INTRODUCTION: LIMITATIONS OF THE TWO-YEAR BIOASSAY
There has now been about 25 years of effort utilizing long-term rodent bioassays to identify potential carcinogens. These efforts have yielded a substantial knowledge base that can be used to improve our understanding of carcinogenesis. I believe that there are several important observations and inferences that can be drawn from an analysis of the available data. They are listed in a canonical form here but can be reconstructed from published literature.
Specific patterns of inheritance of inbred rodent lines can influence the results of carcinogenesis bioassays. The specific genetic influences are related to spontaneous tumors and strain-specific responses to chemicals. This assertion is primarily seen in the dichotomous (i.e., single species) responses in the 2 species assays. Strainor species-specific responses are one of the major confounding factors in extrapolating bioassay results to human risk. Chemical structure can be a principal determinant of mutagenicity and carcinogenicity for many chemicals. For many chemicals, such data can be used to predict carcinogenic potential. Predictive certainty is enhanced by unambiguous in vitro evidence of mutagenicity and relatively high toxicity seen in acute or subchronic toxicity assays in rodents. Chemicals demonstrating these aggregate properties are often carcinogenic in rodent bioassays and are found prominently among chemicals classified as human carcinogens.
A large number of chemicals do not show structural features, in vitro genotoxicity, or systemic toxicity that can be used to predict potential carcinogenicity, even though some of these chemicals have been carcinogens in bioassays. Such nongenotoxic carcinogens often induce strain-, species-, or route-specific carcinogenic effects.
Chemicals inducing carcinogenic effects in long-term bioassays in both rats and mice (trans-species carcinogens) have the greatest potential for carcinogenesis effects in other species and in humans. A high proportion of such chemicals are toxic and mutagenic and are predictable carcinogens.
SHORT-TERM TRANSGENIC BIOASSAYS
The application of short-term alternative bioassays should be geared toward the identification of trans-species carcinogens and to distinguish them unambiguously from noncarcinogens. The identification of chemicals that induce carcinogenic effects in only 1 of the 2 conventional bioassay species is problematic because I am proposing that such cancers are generally the consequence of speciesor strain-specific genetic influences. While the data that have been published to date on the responses of transgenic or knockout mouse lines to chemicals are limited, the results are indicative of specific responses to carcinogens. The 3 models that have been studied most extensively are the p53-deficient, ras H2 (human cHa ras), and TG.AC (v-Ha ras) lines that have shown clearly nonrandom tumor responses.
A scheme that can be applied for the use of transgenic bioassays is as follows:
. Phase 1-Use of chemical structure, in vitro and in vivo genetic toxicity, subchronic toxicity, and target organ pathology. Data can lead to general prediction of carcinogenic potential.
Phase 2-Evaluation of an agent at the maximum tolerated dose and decremental doses in p53+/-and TG.AC bioassays (6-mo exposure).
Positive results in both is indicative of a mutagenic carcinogen. Negative results in both is indicative of a noncarcinogen. Positive in TG.AC only is indicative of a nonmutagenic carcinogen.
INTERLABORATORY COMPARISONS AND EVALUATION STRATEGY
Validation of this scheme can be achieved by selecting specific chemicals or drugs for which conventional (rat and mouse) bioassay results are available. A more objective approach is to assay chemicals that are currently undergoing long-term bioassays and to evaluate the results of both types of bioassays concurrently with the stated objective for the transgenic models of detecting transspecies carcinogens but not responding to noncarcinogens. Such validation can be achieved best by a multiple laboratory effort in which the repeatability and portability of the methods are established for a few chemicals tested in common between the laboratories and transgenic mod-els. Each laboratory can then evaluate agents of specific interest to them with the knowledge that results can be compared to those obtained in other laboratories. Without establishing a common database for some &dquo;core chemicals,&dquo; comparisons among models and among laboratories will not be meaningful. We should learn from the history of validation efforts in genetic toxicology and agree prospectively to conduct a coordinated evaluation/ validation effort. The advantages of such collaboration are both scientific and economic. The National Institute of Environmental Health Sciences has established an initial effort in this direction and is open to the addition of more collaborators.
ADVANTAGES OF TRANSGENIC BIOASSAYS
The principal properties of these models that justify their application as transgenic bioassays are that they possess genotypes that are directly susceptible to carcinogenic effects and their phenotypes allow direct measurement of tumor induction. Both the p53 and ras genes play critical roles in neoplasia in both rodents and humans.
The chemicals tested to date show that tumors can be induced at specific sites with relatively short exposures. I believe that transgenic bioassays minimize the influence of strainand/or species-specific genetic effects by utilizing oncogenes or tumor suppressor genes as targets and by responding to carcinogens prior to the development of strain-specific spontaneous tumors. It is undoubtedly going to be found that different genetic backgrounds will influence the penetrance or expression of transgenes, but I do not believe that it will impair the capacity of the models to distinguish trans-species carcinogens and noncarcinogens. The transgenic models can also provide mechanistic inferences about the action of carcinogens.
The preceding advantages will not apply to the use of single-sex dual species assays (i.e., male rat and female mouse). Such assays will continue to require 2-yr exposures followed by complete postmortem examinations and the application of statistical methods to distinguish what may be induced versus spontaneous tumors. They will thus perpetuate the complexity of the conventional 2-yr assay with only modest economic gain. In conclusion, the tools of molecular genetics have provided new models with which to distinguish carcinogens and noncarcinogens. Transgenic models are best suited to shortterm bioassays predicated on the unambiguous detection of most chemicals with trans-species carcinogenic potential. Their use minimizes the strain-and/or species-specific influences encountered in the use of inbred rodents in 2-yr bioassays. They should not be evaluated against the full range of long-term bioassay chemicals that resulted in such strainor species-specific effects; rather, they should be evaluated against a strategy that requires clear distinction between trans-species carcinogens and noncarcinogens. The transgenic models may also be used to infer the mechanistic effects of chemicals and to identify susceptibility or modifier genes that influence the development or progression of tumors. The main impediment to the application of transgenic bioassays is the development of sufficient data to have confidence in the value of negative responses. Such data should be best developed by cooperative and collaborative efforts.
Identifying Potential Human Carcinogens&mdash;The
Role of Genetically Altered Rodents* The pioneering of genetically altered mice for use as abbreviated carcinogenicity bioassays represents a major achievement by Tennant and his colleagues. The future of rodent carcinogenicity bioassays clearly lies in this direction. The proposal by Tennant that changes should now be made to the standard rodent bioassay, based on the preliminary results of studies using 2 of these abbreviated assays, forms the basis of the following discussion.
There has been no recent or rigorous justification for why the standard carcinogenicity bioassay of chemicals involves the use of 2 rodent species, usually rats and mice. Presumably, this arose out of the fear that use of a single species would leave a significant number of potential human carcinogens undetected. Equally, it was presumably also felt that this danger was not so great as to require the use of 3 or more species. As the 2-species database has grown, 2 things have emerged. First is that
